TABLE 2.
Univariate and multivariate predictors of early AF recurrence
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p‐value | OR | 95% CI | p‐value | |
| Demographic variables | ||||||
| Age, per year | 0.999 | 0.975–1.024 | .959 | 0.983 | 0.951–1.015 | .296 |
| Male sex | 1.725 | 0.946–3.144 | .075 | 1.343 | 0.620–2.910 | .455 |
| BMI, per kg/m2 | 0.989 | 0.915–1.069 | .779 | |||
| CHA2DS2‐VASc score, per 1 point | 0.922 | 0.687–1.237 | .587 | |||
| CHA2DS2‐VASc score ≥2, | 0.777 | 0.443–1.363 | .380 | |||
| Previous ECV | 0.728 | 0.256–2.070 | .551 | |||
| AF duration, per month | 1.003 | 0.995–1.010 | .499 | |||
| >6 months | 1.018 | 0.626–1.656 | .943 | |||
| >12 months | 1.372 | 0.830–2.265 | .217 | |||
| >24 months | 1.238 | 0.723–2.120 | .437 | |||
| Medical history | ||||||
| Hypertension | 0.787 | 0.481–1.288 | .340 | |||
| Diabetes | 1.592 | 0.820–3.091 | .170 | 1.558 | 0.718–3.380 | .262 |
| Coronary artery disease | 0.646 | 0.040–10.445 | .759 | |||
| Stroke/transient ischemic attack | 2.476 | 0.674–9.091 | .172 | 3.343 | 0.834–13.393 | .088 |
| Antiarrhythmic drugs after ECV | ||||||
| Flecainide | 0.740 | 0.386–1.419 | .365 | |||
| Propafenone | 2.142 | 1.225–3.747 | .008 | 1.472 | 0.679–3.193 | .327 |
| Amiodarone | 0.586 | 0.356–0.964 | .035 | 1.047 | 0.524–2.091 | .897 |
| Dronedarone | 1.147 | 0.464–2.836 | .766 | |||
| Echocardiographic parameters | ||||||
| LVEF, per percent | 1.015 | 0.989–1.042 | .251 | |||
| LA diameter, per mm | 0.985 | 0.949–1.022 | .425 | |||
| LA diameter >40 mm | 1.295 | 0.649–2.586 | .463 | |||
| LAVI, per ml/m2 | 1.002 | 0.987–1.018 | .771 | |||
| Electrocardiographic parameters | ||||||
|
Maximum PWD in limb leads , per ms |
1.079 | 1.053–1.106 | <.001 | 1.086 | 1.019–1.157 | .012 |
|
Maximum PWD in precordial leads, per ms |
1.061 | 1.039–1.083 | <.001 | 0.979 | 0.929–1.032 | .436 |
| Duration of PTF, per ms | 1.060 | 1.039–1.081 | <.001 | 1.003 | 0.970–1.037 | .855 |
| PTF, per ms × mm | 1.032 | 1.021–1.043 | <.001 | 1.019 | 1.004–1.033 | .011 |
|
Maximum P‐wave amplitude in limb leads, per mV |
0.137 | 0.001–13.464 | .396 | |||
| PR interval, per ms | 1.004 | 0.997–1.011 | .277 | |||
| QRS duration, per ms | 0.999 | 0.983–1.015 | .882 | |||
| QT interval, per ms | 0.995 | 0.989–1.001 | .075 | 0.995 | 0.987–1.003 | .234 |
| Corrected QT interval, per ms | 0.997 | 0.991–1.004 | .418 | |||
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHA2DS2‐VASc score, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65–74 years, sex category; ECV, electrical cardioversion; LA, left atrium; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; PTF, P‐terminal force; PWD, P‐wave duration.